SINGAPORE, Oct. 3, 2024 /PRNewswire/ -- Traveloka, Southeast Asia's leading travel platform, will showcase its business-to-business (B2B) platform at ITB Asia from October 23 to 25 at Marina Bay Sands Convention Centre, Singapore.
During the event, global travel partners will have the opportunity to explore how the Traveloka Partners Network can serve as their gateway to Southeast Asia's vast travel market, providing access to a wide range of airlines, accommodations, and travel activities.
The Traveloka Partners Network is designed specifically to support B2B partnerships and meet the diverse needs of the travel ecosystem. The platform offers flexible Application Programming Interfaces (APIs), advanced technical tools, and a powerful search engine, ensuring seamless access to a comprehensive range of travel services. Leveraging Traveloka's trusted experience in the region, the platform unlocks the immense potential of Southeast Asia's travel market for its partners.
"Collaboration is the cornerstone of the Traveloka Partners Network," said Caesar Indra, President, Traveloka. "By understanding our partners' unique needs, we provide solutions that drive mutual success. Our commitment to advanced technology, comprehensive booking management tools, and dedicated customer support ensures that our partners and their customers benefit from a seamless, integrated travel experience."
The Traveloka Partners Network offers robust, customizable solutions that empower businesses to integrate Traveloka's services, such as flight bookings and hotel reservations, directly into their platforms. The B2B API is fast, reliable, and easy to implement, giving travel agencies and businesses seamless access to Southeast Asia's growing tourism market.
Additionally, the Redirection and MiniApp Service allow partners to embed Traveloka booking features via a simple link, minimizing development costs while ensuring a smooth user experience. These solutions enable Traveloka's partners to expand their reach and enhance their offerings effortlessly.
PKFARE (a DerbySoft Company), an innovative global travel product aggregator, is one example who has experienced remarkable success through the Traveloka Partners Network, achieving triple-digit growth since the resumption of travel post-pandemic.
By leveraging Traveloka's extensive reach and competitive direct contract inventory, PKFARE has expanded its customer base and optimized its operational efficiency, marking a pivotal milestone in its growth journey. This partnership exemplifies how collaboration with the Traveloka Partners Network can drive tangible results and foster sustained business growth.
Founded in 2012, Traveloka has grown rapidly to serve millions of customers across Indonesia, Thailand, Singapore, Vietnam, Malaysia, the Philippines, and Australia. With over 20 product lines and over 40 payment methods available, Traveloka has become the region's leading travel platform, achieving nearly 50 million monthly active users (MAU) and nearly 140 million app downloads across Southeast Asia.
About Traveloka
Traveloka is Southeast Asia's leading travel platform, empowering consumers to explore, book, and enjoy a wide range of travel products. The platform offers extensive transportation options, including flights, buses, trains, car rentals, and airport transfers. Traveloka's accommodation offerings are equally broad, encompassing hotels, apartments, guest houses, homestays, resorts, and villas. Additionally, the platform enhances the travel experience by offering cruise packages and access to various local attractions, such as theme parks, museums, day tours, and more.
Founded in Indonesia in 2012, Traveloka has expanded its operations to Thailand, Vietnam, Singapore, Malaysia, Australia, and the Philippines. The company is committed to providing exceptional customer service with 24/7 support available in local languages and acceptance of over 40 payment methods. With nearly 140 million app downloads and nearly 50 million monthly active users, Traveloka stands as one of the most popular travel apps in the region.
For more information, please visit Traveloka.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Unlocking Southeast Asia: Traveloka's B2B Platform to be Showcased at ITB Asia
|
Accomplished medical research leader will oversee NCCN programs to advance clinical trials and improve the quality, effectiveness, and accessibility of cancer care.
PLYMOUTH MEETING, Pa., April 9, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers devoted to patient care, research, and education—announced the selection of Nancy L. Lewis, MD, MBS, FACP, as new Chief Scientific Officer (CSO).
Dr. Lewis is an experienced biomedical researcher with expertise in clinical trials for treating solid tumors and hematologic malignancies. She most recently served as Senior Clinical Program Leader for Novartis Pharmaceuticals, after several years as an Associate Professor for various prestigious academic cancer centers. She holds degrees from Penn State University, Temple University School of Medicine, and Rutgers University. Dr. Lewis completed residency at the University of Rochester and Fellowship at Fox Chase Cancer Center—one of NCCN's founding Member Institutions.
"This is a pivotal time for cancer research; there are many successes to build on yet so much still to do. Dr. Lewis is the perfect person to oversee the work we do to foster innovation and knowledge discovery that improves the lives of people with cancer," said Crystal S. Denlinger, MD, CEO, NCCN. "She will be an important asset to our leadership team as she helps us ensure our research and clinical programs continue to advance outcomes in oncology around the world."
Dr. Lewis has previously been honored with awards from some of the foremost cancer organizations across the country, including the American Association for Cancer Research (AACR), The American Society of Clinical Oncology (ASCO), and the American Cancer Society (ACS).
As CSO, Dr. Lewis will assist in the NCCN Oncology Research Program (ORP) as well as key aspects of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Guidelines for Patients®. She will have oversight of the NCCN Biomarkers Compendium®; NCCN Radiation Therapy Compendium™, and NCCN Imaging Appropriate Use Criteria™. Dr. Lewis will also assist with NCCN's Continuing Medical Education Program and with relevant global and policy initiatives.
"I am thrilled to join the National Comprehensive Cancer Network and contribute to its extraordinary legacy of advancing high‑quality cancer care," said Dr. Lewis. "I look forward to working with NCCN's exceptional collaborators to tackle emerging challenges and drive innovative solutions that improve the lives of patients everywhere."
Dr. Lewis will succeed Dr. Denlinger who previously held the position of CSO before becoming CEO for the organization. Dr. Lewis will assume her new role in May 2026.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org
Accomplished medical research leader will oversee NCCN programs to advance clinical trials and improve the quality, effectiveness, and accessibility of cancer care.
PLYMOUTH MEETING, Pa., April 9, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers devoted to patient care, research, and education—announced the selection of Nancy L. Lewis, MD, MBS, FACP, as new Chief Scientific Officer (CSO).
Dr. Lewis is an experienced biomedical researcher with expertise in clinical trials for treating solid tumors and hematologic malignancies. She most recently served as Senior Clinical Program Leader for Novartis Pharmaceuticals, after several years as an Associate Professor for various prestigious academic cancer centers. She holds degrees from Penn State University, Temple University School of Medicine, and Rutgers University. Dr. Lewis completed residency at the University of Rochester and Fellowship at Fox Chase Cancer Center—one of NCCN's founding Member Institutions.
"This is a pivotal time for cancer research; there are many successes to build on yet so much still to do. Dr. Lewis is the perfect person to oversee the work we do to foster innovation and knowledge discovery that improves the lives of people with cancer," said Crystal S. Denlinger, MD, CEO, NCCN. "She will be an important asset to our leadership team as she helps us ensure our research and clinical programs continue to advance outcomes in oncology around the world."
Dr. Lewis has previously been honored with awards from some of the foremost cancer organizations across the country, including the American Association for Cancer Research (AACR), The American Society of Clinical Oncology (ASCO), and the American Cancer Society (ACS).
As CSO, Dr. Lewis will assist in the NCCN Oncology Research Program (ORP) as well as key aspects of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Guidelines for Patients®. She will have oversight of the NCCN Biomarkers Compendium®; NCCN Radiation Therapy Compendium™, and NCCN Imaging Appropriate Use Criteria™. Dr. Lewis will also assist with NCCN's Continuing Medical Education Program and with relevant global and policy initiatives.
"I am thrilled to join the National Comprehensive Cancer Network and contribute to its extraordinary legacy of advancing high‑quality cancer care," said Dr. Lewis. "I look forward to working with NCCN's exceptional collaborators to tackle emerging challenges and drive innovative solutions that improve the lives of patients everywhere."
Dr. Lewis will succeed Dr. Denlinger who previously held the position of CSO before becoming CEO for the organization. Dr. Lewis will assume her new role in May 2026.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Nancy L. Lewis, MD, MBS, FACP, Named New Chief Scientific Officer for National Comprehensive Cancer Network (NCCN)
